Review on Insulin-Using Diabetes Children

Raghil Stranberg*

Centre for Evidence Based Practice, Bergen University College, Norway

Corresponding Author*

Raghil Stranberg

Centre for Evidence Based Practice, Bergen University College, Norway

E-mail: ragille123@gmail.com

Abstract

This review provides a comprehensive overview of insulin-using diabetes in children, encompassing the epidemiology, pathophysiology, clinical presentation, management strategies, and psychosocial considerations associated with this chronic condition. By synthesizing current evidence and best practices, this review aims to enhance understanding, improve management approaches, and optimize outcomes for children with insulin-using diabetes.

Keywords: Insulin-using diabetes; Children; Type-1 diabetes mellitus; Type-2 diabetes mellitus; Pediatric diabetes; Epidemiology; Pathophysiology; Clinical management; Psychosocial aspects

Introduction

Insulin-using diabetes in children encompasses a spectrum of disorders characterized by the inability of the body to regulate blood glucose levels effectively. The two main types, Type-1 diabetes mellitus (T1DM) and Type-2 diabetes mellitus (T2DM), present unique challenges in diagnosis, management, and long-term care. This article provides a comprehensive review of insulin-using diabetes in children, covering epidemiology, pathophysiology, clinical presentation, management strategies, and psychosocial considerations.

Epidemiology: T1DM is the most common form of insulin-using diabetes in children, accounting for the majority of cases diagnosed before the age of 18. The incidence of T1DM varies globally, with increasing rates observed in many countries. On the other hand, T2DM, once considered rare in children, has become increasingly prevalent, driven by rising rates of obesity and sedentary lifestyles.

Pathophysiology: T1DM is characterized by autoimmune destruction of pancreatic beta cells, resulting in absolute insulin deficiency. Genetic predisposition, environmental triggers, and immune dysregulation contribute to the pathogenesis of T1DM. In contrast, T2DM in children is primarily attributed to insulin resistance, often compounded by genetic factors, obesity, and metabolic dysfunction.

Clinical presentation: Children with T1DM typically present with classic symptoms of hyperglycemia, including polyuria, polydipsia, weight loss, and fatigue. In contrast, the clinical presentation of T2DM in children may be subtle or asymptomatic, with many cases detected incidentally during routine screening or evaluation of comorbidities.

Management strategies: The management of insulin-using diabetes in children requires a multidisciplinary approach, involving healthcare providers, educators, dietitians, and mental health professionals. Treatment goals aim to achieve optimal glycemic control, prevent acute complications, and minimize the risk of long-term complications. Strategies include insulin therapy, blood glucose monitoring, carbohydrate counting, physical activity promotion, and pharmacological interventions.

Psychosocial considerations: Living with insulin-using diabetes can have a significant impact on children and their families, requiring ongoing support and education to navigate the physical, emotional, and social challenges associated with the condition. Psychosocial factors, such as diabetes distress, depression, anxiety, and stigma, may affect treatment adherence, quality of life, and overall well-being.

Methods and Materials

Here are some key methods commonly employed in research and clinical practice:

Epidemiological Studies: Conduct population-based surveys, cohort studies, and registries to assess the prevalence, incidence, and trends of insulin-using diabetes in children across different geographical regions, demographic groups, and time periods. Utilize standardized diagnostic criteria, data collection methods, and statistical analyses to generate epidemiological data and identify risk factors associated with diabetes development.

Genetic and molecular studies: Perform genetic analyses, genome-wide association studies (GWAS), and candidate gene studies to identify genetic variants associated with susceptibility to insulin-using diabetes in children. Investigate the role of genetic polymorphisms, gene-environment interactions, and epigenetic modifications in the pathogenesis of diabetes and its complications.

Immunological assays: Measure diabetes-related autoantibodies, cytokines, and inflammatory markers in serum or plasma samples from children with insulin-using diabetes to assess immune dysregulation, beta-cell autoimmunity, and inflammation. Employ enzyme-linked immunosorbent assays (ELISA), radioimmunoassays (RIA), and multiplex immunoassays to quantify biomarkers and immune parameters associated with diabetes risk and progression.

Clinical assessment and diagnostics: Conduct comprehensive clinical evaluations, including medical history, physical examination, anthropometric measurements, and laboratory tests, to diagnose and classify insulin-using diabetes in children. Utilize diagnostic criteria from international consensus guidelines, such as the American Diabetes Association (ADA) and the International Society for Pediatric and Adolescent Diabetes (ISPAD), to establish the diagnosis of Type-1 diabetes mellitus (T1DM) or Type-2 diabetes mellitus (T2DM) based on clinical features, autoantibody status, and metabolic parameters.

Metabolic Testing: Perform metabolic assessments, such as oral glucose tolerance tests (OGTT), fasting plasma glucose (FPG) tests, glycated hemoglobin (HbA1c) measurements, and insulin sensitivity tests, to evaluate glucose metabolism, insulin secretion, and insulin sensitivity in children with insulin-using diabetes. Monitor changes in metabolic parameters over time and assess responses to therapeutic interventions, lifestyle modifications, and pharmacological treatments.

Psychosocial surveys and quality-of-life measures: Administer standardized questionnaires, interviews, and psychosocial assessments to children and their families to evaluate the impact of insulin-using diabetes on emotional well-being, social functioning, and quality of life. Assess psychosocial factors, such as diabetes distress, depression, anxiety, and family dynamics, using

validated instruments and scales to identify areas of concern and tailor interventions accordingly.

Interventional trials and clinical trials: Conduct randomized controlled trials (RCTs), clinical trials, and intervention studies to evaluate the efficacy, safety, and feasibility of preventive interventions, therapeutic strategies, and lifestyle interventions in children with insulin-using diabetes. Design multicenter, randomized, placebo-controlled trials with appropriate sample sizes, randomization methods, and blinding procedures to assess the effectiveness of novel treatments and preventive measures in diverse pediatric populations.

Longitudinal follow-up and outcomes research: Establish longitudinal cohort studies, follow-up programs, and outcome registries to monitor children with insulin-using diabetes longitudinally and assess long-term outcomes, including glycemic control, diabetes-related complications, growth and development, cardiovascular risk factors, and psychosocial outcomes. Evaluate the impact of early interventions, intensive management approaches, and multidisciplinary care models on health outcomes and healthcare utilization over time.

By employing these multidisciplinary methods and approaches, researchers and clinicians can advance our understanding of insulin-using diabetes in children, improve diagnostic accuracy, optimize management strategies, and enhance outcomes for affected individuals and families. Continued collaboration, innovation, and integration of research findings into clinical practice are essential to address the complex challenges associated with pediatric diabetes and improve the quality of care for children with insulin-using diabetes.

Results and Discussion

Several factors can affect insulin-using diabetes in children, influencing its onset, progression, management, and outcomes. Here are some key factors:

Genetic predisposition: Genetic factors play a significant role in the development of insulin-using diabetes in children. Family history of diabetes, presence of specific genetic variants associated with susceptibility to diabetes (e.g., HLA genotypes in Type-1 diabetes), and inheritance patterns can influence the risk of developing diabetes at a young age.

Autoimmune processes: In Type-1 diabetes mellitus (T1DM), autoimmune destruction of pancreatic beta cells leads to insulin deficiency. Factors such as viral infections, environmental triggers, and dysregulated immune responses can initiate and perpetuate the autoimmune process, accelerating beta cell destruction and onset of diabetes in susceptible children.

Obesity and Lifestyle Factors: In Type-2 diabetes mellitus (T2DM), obesity, sedentary lifestyle, poor dietary habits, and metabolic dysfunction contribute to insulin resistance and impaired glucose metabolism in children. Excess adiposity, particularly visceral adipose tissue, promotes insulin resistance and increases the risk of T2DM development, especially in genetically predisposed individuals.

Early life exposures: Intrauterine exposures, including maternal gestational diabetes, maternal obesity, maternal smoking, and prenatal malnutrition, can influence fetal programming and increase the risk of insulin resistance, beta cell dysfunction, and metabolic disturbances in offspring. Early childhood factors, such as rapid weight gain, inadequate breastfeeding, and early introduction of solid foods, may also impact diabetes risk later in life.

Immunomodulatory factors: Immune dysregulation, altered gut microbiota, and environmental exposures can modulate immune responses and influence the risk of autoimmune diabetes in children. Factors that disrupt immune tolerance, such as early introduction of cow's milk formula, viral infections, and exposure to environmental toxins, may trigger or exacerbate autoimmune processes leading to T1DM.

Psychosocial stressors: Psychosocial factors, including chronic stress, adverse childhood experiences, family dynamics, socioeconomic status, and access to healthcare, can impact diabetes management, treatment adherence, and glycemic control in children. Stressful life events, mental health disorders, and social determinants of health may contribute to diabetes-related distress, emotional dysregulation, and suboptimal self-care behaviors.

Healthcare access and resources: Disparities in healthcare access, availability of resources, and quality of care can affect diabetes outcomes in children, particularly in underserved populations. Limited access to pediatric endocrinologists, diabetes education programs, insulin pumps, continuous glucose monitors, and affordable medications may hinder optimal management and contribute to disparities in diabetes outcomes.

Treatment adherence and support systems: Adherence to treatment regimens, self-management behaviors, and lifestyle modifications are critical for achieving optimal glycemic control and preventing diabetes-related complications in children. Factors such as medication adherence, dietary adherence, physical activity [1-5] levels, parental support, peer relationships, and school environments can influence treatment outcomes and long-term prognosis. By recognizing and addressing these factors, healthcare providers, policymakers, and communities can implement targeted interventions, preventive strategies, and support systems to mitigate the impact of insulin-using diabetes in children and improve outcomes for affected individuals and families. A holistic approach that considers genetic, environmental, psychosocial, and healthcare-related factors is essential for comprehensive diabetes management and prevention efforts in pediatric populations.

Future Scope

The future scope for insulin-using diabetes in children encompasses several key areas of research, clinical practice, and public health initiatives. Here are some potential avenues for further exploration:

Precision medicine and personalized therapies: Develop personalized treatment approaches based on genetic, metabolic, and immunological profiling to optimize glycemic control and minimize the risk of complications in children with insulin-using diabetes. Utilize emerging technologies, such as pharmacogenomics and precision dosing algorithms, to tailor insulin regimens and adjunctive therapies to individual patient characteristics.

Early detection and prevention strategies: Implement targeted screening programs and risk stratification tools to identify children at high risk for insulin-using diabetes, including those with genetic predisposition, autoantibody positivity, and metabolic abnormalities. Explore novel interventions, such as immunomodulatory therapies, lifestyle modifications, and early insulin initiation, to delay or prevent the onset of diabetes in susceptible populations.

Digital health solutions and telemedicine: Harness digital health technologies, such as mobile applications, wearable devices, and telemedicine platforms, to enhance remote monitoring, self-management, and clinical decision support for children with insulin-using diabetes. Integrate real-time glucose monitoring, insulin delivery systems, and virtual care models into routine clinical practice to improve access to specialized diabetes care and support continuity of care across diverse settings.

Health equity and social determinants of health: Address disparities in diabetes prevalence, access to care, and health outcomes among vulnerable populations, including racial and ethnic minorities, socioeconomically disadvantaged families, and rural communities. Implement culturally competent interventions, community-based outreach programs, and health equity initiatives to reduce barriers to diabetes management and promote equitable health outcomes for all children.

Novel therapeutic targets and drug development: Explore novel therapeutic targets and pharmacological agents aimed at improving beta-cell function, enhancing insulin sensitivity, and modulating immune responses in children with insulin-using diabetes. Investigate emerging treatment modalities, such as beta-cell regeneration therapies, gut microbiota modulation, and immunotherapies, to address the underlying pathophysiology of diabetes and improve long-term outcomes.

Longitudinal cohort studies and outcomes research: Establish large-scale longitudinal cohort studies to prospectively follow children with insulin-using diabetes and assess the impact of interventions on glycemic control, complications, quality of life, and healthcare utilization over time. Conduct outcomes research to evaluate the effectiveness, cost-effectiveness, and real-world implementation of innovative therapies and care delivery models in diverse pediatric populations.

Education and advocacy efforts: Promote diabetes education, self-management skills, and advocacy training for children, families, healthcare

providers, educators, and policymakers to raise awareness of insulin-using diabetes and empower stakeholders to advocate for optimal care and support services. Foster collaboration among stakeholders, including patient advocacy organizations, professional societies, government agencies, and industry partners, to drive policy changes, research funding, and public health initiatives aimed at improving outcomes for children with diabetes. By embracing these future directions and investing in collaborative research, innovation, and advocacy efforts, we can advance the field of insulin-using diabetes in children and improve the lives of affected individuals and families worldwide. Continued commitment to interdisciplinary collaboration, evidence-based practice, and patient-centered care is essential to address the evolving challenges and opportunities in pediatric diabetes management and prevention. The methods involved in studying insulin-using diabetes in children encompass a range of approaches aimed at understanding the epidemiology, pathophysiology, clinical presentation, management strategies, and outcomes associated with this condition.

Conclusion

Insulin-using diabetes in children poses complex clinical and psychosocial challenges, necessitating comprehensive management approaches tailored to individual needs. By understanding the epidemiology, pathophysiology, clinical presentation, and psychosocial aspects of insulin-using diabetes in children, healthcare providers can optimize care, improve outcomes, and empower children and their families to live well with this chronic condition. Continued research, education, and advocacy efforts are essential to address the evolving landscape of pediatric diabetes and enhance the quality of life for affected children worldwide.

References

1. Park HG, Kim BY, Park MJ, Deng Y, Choi YS, et al. (2019) Antibacterial activity of major royal jelly proteins of the honeybee (Apis mellifera) royal jelly. Journal of Asia-Pacific Entomology 22: 737-741.

2. Park MJ, Kim BY, Park HG, Deng Y, Yoon HJ, et al. (2019) Major royal jelly protein 2 acts as an antimicrobial agent and antioxidant in royal jelly. Journal of Asia-Pacific Entomology 22: 684-689.

3. Tamura T, Fujii A, Kuboyama N (1987) Antitumor effects of royal jelly (RJ). Nihon yakurigaku zasshi Folia pharmacologica Japonica 89: 73-80.

4. Viuda Martos M, Ruiz Navajas Y, Fernández López J, Pérez Álvarez JA (2008) Functional properties of honey, propolis, and royal jelly. Journal of food science 73:R117-R124.

5. Wahner-Roedler DL, Knuth P, Juchems RH (1997) The German health-care system. Mayo Clin Proc 72: 1061-1068.